IMVT vs. CRSP, IBRX, KRYS, SWTX, HALO, ACLX, IOVA, APGE, DNLI, and UTZ
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), Halozyme Therapeutics (HALO), Arcellx (ACLX), Iovance Biotherapeutics (IOVA), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), and Utz Brands (UTZ).
CRISPR Therapeutics (NASDAQ:CRSP) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings.
CRISPR Therapeutics received 351 more outperform votes than Immunovant when rated by MarketBeat users. However, 76.22% of users gave Immunovant an outperform vote while only 65.43% of users gave CRISPR Therapeutics an outperform vote.
Immunovant's return on equity of -11.56% beat CRISPR Therapeutics' return on equity.
CRISPR Therapeutics presently has a consensus target price of $73.57, suggesting a potential upside of 33.72%. Immunovant has a consensus target price of $49.00, suggesting a potential upside of 72.29%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Immunovant is more favorable than CRISPR Therapeutics.
69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 4.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, CRISPR Therapeutics had 9 more articles in the media than Immunovant. MarketBeat recorded 21 mentions for CRISPR Therapeutics and 12 mentions for Immunovant. Immunovant's average media sentiment score of 0.78 beat CRISPR Therapeutics' score of 0.59 indicating that CRISPR Therapeutics is being referred to more favorably in the media.
CRISPR Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
CRISPR Therapeutics has higher revenue and earnings than Immunovant. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.
Summary
CRISPR Therapeutics beats Immunovant on 9 of the 16 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
